Reported 1 day ago
Novo Nordisk shares rose by 2.9% after Berenberg Bank upgraded the stock to a buy, citing that the company's past setbacks have been factored into a more realistic growth outlook. The bank now considers Novo Nordisk its preferred choice in the obesity market, especially as the stock trades at a lower valuation with a dividend yield of 3%. However, analysts warn that there's still uncertainty regarding its potential for growth, suggesting that investors should weigh their options carefully.
Source: YAHOO